Abstract 13273: APOLLO-B, a Study of Patisiran in Patients With Transthyretin Cardiac Amyloidosis: Primary Long-Term Results From the Open-Label Extension Period
Rebecca R. Hung(Vanderbilt University Medical Center), Matthew J. Maurer(Mayo Clinic in Arizona), John L. Berk(Boston University), Elena Yureneva(British Heart Foundation), Marianna Fontana(Amyloidosis Foundation), Edileide de Barros Correia(Instituto Dante Pazzanese de Cardiologia), Julian D. Gillmore(Alnylam Pharmaceuticals (United States)), Matthew T. White(Alnylam Pharmaceuticals (United States)), Brian Drachman(Penn Presbyterian Medical Center), Patrick Y. Jay(Washington University in St. Louis), Cláudio Tinoco Mesquita(Universidade Federal Fluminense), Marcus V Simoes(Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo), Marianne T. Sweetser(Alnylam Pharmaceuticals (United States))
Cited by 6
Related Papers
Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis
|New England Journal of Medicine|2018|2.9k
Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy
|New England Journal of Medicine|2018|2.8k
Nonbiopsy Diagnosis of Cardiac Transthyretin Amyloidosis
|Circulation|2016|2k
CRISPR-Cas9 In Vivo Gene Editing for Transthyretin Amyloidosis
|New England Journal of Medicine|2021|1.7k
Inotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis
|New England Journal of Medicine|2018|1.4k